Ursodeoxycholsure

UDCA · URSODIOL · Ursodeoxycholic · URSODESOXYCHOLIC ACID · URSODEOXYCHOLATE · Tauroursodiol · 3-alpha,7-beta-dihydroxy-5-beta-cholanoicacid · Urosodeoxycholic Acid

https://huagongshe.com/de/chemical/31401

Identifikatoren & physikalische Daten

CAS No.	128-13-2
Summenformel	C24H40O4
Durchschnittliche Molmasse	392,6 g/mol
Monoisotopische Masse	392,29265975 g/mol
SMILES	C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
InChIKey	RUDATBOHQWOJDD-UZVSRGJWSA-N
PubChem CID	31401
ChEMBL	CHEMBL1551
ChEBI	CHEBI:9907
EC No.	204-879-3
DTXSID	DTXSID6023731
Lokaler Name	Ursodeoxycholsure

Chemische & physikalische Eigenschaften

XLogP	4,9
Polarare Oberfläche (TPSA)	77,8
H-Brücken-Donoren	3
H-Brücken-Akzeptoren	4
Frei drehbare Bindungen	4
Schwere Atome	28
Formalladung	0
Komplexität	605
LogP (Verteilungskoeffizient)	33.00
Löslichkeit	0.02 mg/mLethanol: 50 mg/mL, clearpractically insoluble
Schmelzpunkt	200-205203 °C203-204 °C (lit.)
Physical Description	Solid
Collision Cross Section	200.0 Å² [M-H]- [CCS Type: DTBuffer gas: N2Ionization: ESI-Dataset: Bile Acids]208.98 Å² [M-H]- [CCS Type: DTMethod: stepped-field]200.9 Å² [M-H]- [CCS Type: DTMethod: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]198.7 Å² [M+Na]+ [CCS Type: DT203.2 Å² [M+Na-H+HCOO]- [CCS Type: DTMethod: single field calibrated]198.3 Å² [M-H]- [CCS Type: DT199.4 Å² [M+Na-H+Cl]- [CCS Type: DT186.8 Å² [M+H-2H2O]+ [CCS Type: DT200.2 Å² [M+HCOO]- [CCS Type: DT205.7 Å² [M+K-H+HCOO]- [CCS Type: DT198.86 Å² [M+K]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]193.71 Å² [M+H]+ [CCS Type: TW196.65 Å² [M+Na]+ [CCS Type: TW
Siedepunkt	437.26°C (rough estimate)
Dichte	0.9985 (rough estimate)
Brechungsindex	60.5 ° (C=2, EtOH)
Flammpunkt	9℃
Lagerbedingungen	2-8°C
Aggregatzustand	Solid. Powder.
pKa (Säurekonstante)	pKa 5.04±0.04(H2O t = 25.0±0.1 I = 0.00)(Approximate)
Farbe	White - almost white.
Merck	14,9889
BRN	3219888
Kosmetik-Inhaltsstoffe Funktionen	SKIN CONDITIONING - MISCELLANEOUSSKIN PROTECTING
InChIKey	RUDATBOHQWOJDD-UZVSRGJWSA-N
SMILES	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
LogP (Verteilungskoeffizient)	3-3.38 at 20℃
CAS Datenbank	128-13-2(CAS DataBase Reference)

Sicherheit & Vorschriften

GHS-Einstufung	This chemical does not meet GHS hazard criteria for 4.5% (2 of 44) of reports.WarningH315 (95.5%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (95.5%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement)Aggregated GHS information provided per 44 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 2 of 44 reports by companies.There are 3 notifications provided by 42 of 44 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Regulatorische Informationen	Status: Active Update: 06-03-2023 https://echa.europa.eu/registration-dossier/-/registered-dossier/5699Status: Active Update: 06-09-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/27118Ursodeoxycholic acid: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Weitere Sicherheitsinformationen	IMAP assessments - Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)-: Environment tier I assessmentIMAP assessments - Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)-: Human health tier I assessment
Hazard Classes and Categories	Skin Irrit. 2 (95.5%)Eye Irrit. 2A (95.5%)
Hepatotoxicity	n multiple clinical trials in a variety of conditions, ursodiol has not been found to cause increases in serum enzyme elevations, worsening of underlying liver disease or clinically apparent liver injury. Nevertheless, there have been rare reports of clinical decompensation in patients with advanced liver disease and cirrhosis started on ursodiol, but the reason for such reactions is not known. In at least one instance, there was recurrence of jaundice on restarting ursodiol. Thus, ursodiol has beneficial effects on several forms of liver disease and has not been convincingly linked to cases of clinically apparent acute liver injury in patients without cirrhosis. There is some concern that ursodiol may be harmful in patients with advanced liver disease (Childs class B and C) and such patients probably should not receive ursodiol.

Anwendungen & Verwendung

Verwenden

Ursodeoxycholic acid (UDCS) is a cell protectant used extensively to mitigate hepatic and biliary diseases. Ursodeoxycholic acid may be used to study its specific activities that range from reduction of cholesterol absorpition, cholesterol gallstone dissolution to suppression of immune response. It is also used as an anticholelithogenic. Epimer with Chenodiol with respect to the hydroxyl group at C7.